cas 2368945-95-1|| where to buy tert-butyl 5-acetamido-3-bromo-pyrrolo[2,3-c]pyridine-1-carboxylate

Product Name:tert-butyl 5-acetamido-3-bromo-pyrrolo[2,3-c]pyridine-1-carboxylate

IUPAC Name:tert-butyl 3-bromo-5-acetamido-1H-pyrrolo[2,3-c]pyridine-1-carboxylate

Packing Unit	Available Stock	Price($)
CM429663-100mg	in stock	ůůǊ
CM429663-250mg	in stock	Ɠŉů

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:2368945-95-1; Molecular Formula:C14H16BrN3O3; Melting Point:-; Smiles Code:CC(=O)NC1=NC=C2N(C=C(Br)C2=C1)C(=O)OC(C)(C)C; Density:

: Catalog Number:CM429663; Molecular Weight:354.2; Boiling Point:; MDL No:MFCD32670499; Storage:

: Azaindoles; Azaindole can be regarded as the biological isostere of indole, and the molecular unit of indole plays a huge role in the life process. Many drug molecules contain indole units. Azaindole is an important heterocyclic intermediate with good biological and medicinal value, and is the core structure of many drugs, such as antitumor drugs, dopamine D4 receptors, kinase inhibitors, thrombin inhibitors, etc. Therefore, it has a wide range of application value in medical research. Azaindole can be regarded as the biological isostere of indole, and the molecular unit of indole plays a huge role in the life process. Many drug molecules contain indole units. Azaindole is an important heterocyclic intermediate with good biological and medicinal value, and is the core structure of many drugs, such as antitumor drugs, dopamine D4 receptors, kinase inhibitors, thrombin inhibitors, etc. Therefore, it has a wide range of application value in medical research.Azaindole

: ABBV-712; TYK2 is an attractive target for various autoimmune diseases as it regulates signal transduction downstream of IL-23 and IL-12 receptors. Selective TYK2 inhibition offers a differentiated clinical profile compared to currently approved JAK inhibitors. Scientists discovered the clinical candidate ABBV-712 in the optimization of selective TYK2 inhibitors targeting the pseudokinase domain.